To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 366 participants.

Also called NCT06500689

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 366 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06500689
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06500689. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-30 (actual); primary completion 2023-11-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
Condition
Essential Hypertension
Intervention (Drug)
Allisartan Isoproxil/Sustained-Release Indapamide
Intervention (Drug)
Allisartan Isoproxil
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06500689
Content hash
7936e5582895be72e4fc11bde9083362f90560cba03d81015f543b40fb3eefc9